Patentability of genes: A European union perspective

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 5, 2015, Pages

  Cole, Paul ^a,b  

^a BOURNEMOUTH UNIVERSITY   (United Kingdom)

^b Lucas and Co   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COURT; EUROPEAN UNION; GENE SEQUENCE; HUMAN; LAW; ONCOGENE; PATENT; UNITED KINGDOM; UNITED STATES; BIOTECHNOLOGY; GENE; LEGISLATION AND JURISPRUDENCE;

BIOTECHNOLOGY; EUROPEAN UNION; GENES; PATENTS AS TOPIC;

EID: 84930503386     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a020891     Document Type: Article

References (5)

1. Ann C. 2006. Patents on human gene sequences in Germany: On bad lawmaking and ways to deal with it. German Law J 7: 279-292. www.germanlawjournal.com/index.php?pageID=11&artID=716.
2. Cole P. 2013. The unacknowledged role of section 112 in the Myriad decisions. patents4life. CIPA J12: 708-712.
3. Cole P. 2014. Myriad, an obvious and patent-friendly interpretation. CIPA J 6: 335-337.
4. Gold ER, Carbone J. 2010. Myriad genetics: In the eye of the policy storm. Genet Med 12: S39-S70.
5. Hirshfeld AH. 2014. Procedure For subject matter eligibility analysis of claims reciting or involving laws of nature: Natural principles, natural phenomena, and/or natural products. www.uspto.gov/patents/law/exam/myriad-mayo_guidance.pdf.